--- title: "藥明康德計劃通過發行零息可轉換債券籌集約 10 億美元" type: "News" locale: "zh-HK" url: "https://longbridge.com/zh-HK/news/286487023.md" description: "藥明康德計劃通過以美元結算的零息可轉換債券籌集約 10 億美元，以增強其產能和能力。這些債券可按初始價格 HK$153 轉換為股份，約佔擴大後 H 股資本的 9.1%。籌集的資金將用於全球擴展和公司用途。摩根士丹利、花旗集團和高盛正在為此次發行提供諮詢" datetime: "2026-05-15T00:53:02.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/286487023.md) - [en](https://longbridge.com/en/news/286487023.md) - [zh-HK](https://longbridge.com/zh-HK/news/286487023.md) --- # 藥明康德計劃通過發行零息可轉換債券籌集約 10 億美元 By Megan Cheah Wuxi AppTec plans to raise around $1 billion by issuing U.S. dollar-settled zero coupon convertible bonds, as it seeks to boost its capacity and capabilities. The Shanghai-based company, which provides drug research, development and manufacturing services, plans to issue the bonds with a principal amount of 6.78 billion yuan, equivalent to $999 million, Wuxi AppTec said Friday. The bonds can be converted to Hong Kong-listed shares at an initial conversion price of 153 Hong Kong dollars per share, or $19.54, subject to adjustments and conditions, said the company, which is listed in both Shanghai and Hong Kong. The conversion price is a premium of around 18% over Wuxi AppTec's Thursday closing price of HK$130.10, the company said. Assuming full conversion of all the bonds at this price, the converted shares will represent around 9.1% of Wuxi's enlarged H-share capital and around 1.7% of its total issued share capital. Wuxi intends to use the net proceeds of around $1.02 billion for global capacity and capability expansion, and general corporate purposes. Morgan Stanley, Citigroup and Goldman Sachs are the banks advising Wuxi on its bond issuance. Wuxi AppTec's shares in Hong Kong closed 5.2% lower at HK$130.10 on Thursday, but are about 32% higher year to date. Write to Megan Cheah at megan.cheah@wsj.com (END) Dow Jones Newswires May 14, 2026 20:41 ET (00:41 GMT) Copyright (c) 2026 Dow Jones & Company, Inc. ### 相關股票 - [02359.HK](https://longbridge.com/zh-HK/quote/02359.HK.md) - [159892.CN](https://longbridge.com/zh-HK/quote/159892.CN.md) - [512010.CN](https://longbridge.com/zh-HK/quote/512010.CN.md) - [520880.CN](https://longbridge.com/zh-HK/quote/520880.CN.md) - [159570.CN](https://longbridge.com/zh-HK/quote/159570.CN.md) - [159837.CN](https://longbridge.com/zh-HK/quote/159837.CN.md) - [516500.CN](https://longbridge.com/zh-HK/quote/516500.CN.md) - [562050.CN](https://longbridge.com/zh-HK/quote/562050.CN.md) - [516930.CN](https://longbridge.com/zh-HK/quote/516930.CN.md) - [512290.CN](https://longbridge.com/zh-HK/quote/512290.CN.md) - [520500.CN](https://longbridge.com/zh-HK/quote/520500.CN.md) - [603259.CN](https://longbridge.com/zh-HK/quote/603259.CN.md) - [MS.US](https://longbridge.com/zh-HK/quote/MS.US.md) - [C.US](https://longbridge.com/zh-HK/quote/C.US.md) - [GS.US](https://longbridge.com/zh-HK/quote/GS.US.md) - [MS-O.US](https://longbridge.com/zh-HK/quote/MS-O.US.md) - [MS-Q.US](https://longbridge.com/zh-HK/quote/MS-Q.US.md) - [MS-E.US](https://longbridge.com/zh-HK/quote/MS-E.US.md) - [MS-I.US](https://longbridge.com/zh-HK/quote/MS-I.US.md) - [MS-L.US](https://longbridge.com/zh-HK/quote/MS-L.US.md) - [MS-P.US](https://longbridge.com/zh-HK/quote/MS-P.US.md) - [MS-A.US](https://longbridge.com/zh-HK/quote/MS-A.US.md) - [MS-F.US](https://longbridge.com/zh-HK/quote/MS-F.US.md) - [MS-K.US](https://longbridge.com/zh-HK/quote/MS-K.US.md) - [C-R.US](https://longbridge.com/zh-HK/quote/C-R.US.md) - [W4VR.SG](https://longbridge.com/zh-HK/quote/W4VR.SG.md) ## 相關資訊與研究 - [藥明康德擬發 67.8 億人民幣零息可轉債，最多增發超一成 H 股](https://longbridge.com/zh-HK/news/286484310.md) - [翰森製藥治療晚期實體瘤藥物臨牀試驗獲批](https://longbridge.com/zh-HK/news/286336046.md) - [藥明康德建議發行人民幣 67.8 億元於 2027 年到期的美元結算零息可轉換債券](https://longbridge.com/zh-HK/news/286482748.md) - [藥明康德擬發行 67.8 億元人民幣 以美元結算零息可轉換債券](https://longbridge.com/zh-HK/news/286487175.md) - [藥明康德零息美元可轉債強勢定價：零利息且需 “倒貼 3.5%”](https://longbridge.com/zh-HK/news/286486297.md)